Danish biotech (Nasdaq: GMAB) on Saturday revealed that US pharma major (AbbVie (NYSE: ABBV) has filed a complaint in the US ...

New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected ...

Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...

Oxford BioTherapeutics has partnered with Roche to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer.

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...

ON ASTRAZENECA ASSAY DEVELOPMENT PROJECTS AND SUCCESSFUL COMPLETION OF EISAI CONTRACTDevelopment of both the prostate cancer androgen receptor assay and the multi-cancer DDR micronuclei assay ...

Ladenburg, Germany, 21 March 2025 – Heidelberg Pharma AG (FSE: HPHA) today published its financial results and Annual Report for fiscal year 2024 (1 December 2023 – 30 November 2024) and its outlook ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...

Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...

The Japanese pharmaceutical company Taiho Pharmaceutical is set to acquire the Swiss antibody-drug conjugate (ADC) company Araris Biotech for $400 million. Taiho and Araris have been collaborating to ...

The pharma will acquire Araris Biotech to gain access to three preclinical ADCs and a linking technology Araris claims is ...